Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Liver crawled time : 13:20 save search
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
Published: 2023-07-17 (Crawled : 13:20) - biospace.com/
TVTX | $5.85 2.27% 2.22% 1.1M
|
Health Technology
|
| O: 5.16%
H: 0.75%
C: -1.43%
MS | News 0 d | $92.09 1.58% 0.07% 4.9M
|
Finance
|
| O: -0.12%
H: 1.42%
C: 0.81%
MIRM | $24.17 1.51% 1.49% 250K
|
Health Technology
|
| O: 1.18%
H: 7.3%
C: 2.18%
rare liver treatment pharmaceuticals acquire therapeutics agreement
ZyVersa Therapeutics Announces a Publication in Hepatology Revealing That Alcohol-induced Extracellular ASC Specks Perpetuate Liver Inflammation and Damage in Alcoholic Hepatitis
Published: 2023-05-04 (Crawled : 13:20) - globenewswire.com
ZVSA | $0.5752 -1.84% -1.88% 240K
|
|
| O: 4.34%
H: 3.09%
C: 3.06%
hepatitis liver publication therapeutics
Alpha Tau Announces Health Canada Authorization for Alpha DaRT Clinical Trial for the Treatment of Liver Metastases
Published: 2023-03-01 (Crawled : 13:20) - globenewswire.com
DRTS | $2.44 -4.69% -4.7% 120K
|
n/a
|
| O: -1.58%
H: 9.23%
C: 9.0%
treatment liver canada health tau trial dart authorization
Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal
Published: 2023-01-24 (Crawled : 13:20) - globenewswire.com
GALT | $3.06 -9.2% -10.31% 310K
|
Health Technology
|
| O: 1.82%
H: 0.0%
C: -0.89%
liver therapeutics
Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis
Published: 2023-01-06 (Crawled : 13:20) - globenewswire.com
MDGL | $213.49 0.68% 0.85% 680K
|
Health Technology
|
| O: 0.18%
H: 3.75%
C: 3.28%
treatment fibrosis liver trial positive nash
Akero Therapeutics to Present Late-Breaking Oral and Poster presentations on EFX Today at AASLD’s The Liver Meeting® 2022Phase 2b HARMONY study presentation selected for inclusion in the Best of the Liver meeting in the NASH/NAFLD category
Published: 2022-11-07 (Crawled : 13:20) - biospace.com/
AKRO | $20.79 0.15% 0.14% 710K
|
Health Technology
|
| O: 2.39%
H: 2.39%
C: -3.12%
meeting liver therapeutics presentation today study
Aligos Therapeutics to Present Nonclinical and Clinical Data for its Chronic Hepatitis B and NASH Portfolio at AASLD’s The Liver Meeting® 2022
Published: 2022-10-21 (Crawled : 13:20) - globenewswire.com
ALGS | $0.801 6.8% 6.83% 470K
|
Health Technology
|
| O: -1.83%
H: 3.74%
C: -2.8%
meeting hepatitis liver therapeutics nash chronic hepatitis b
CymaBay Therapeutics Announces Three Presentations at The Liver Meeting® 2022
Published: 2022-10-03 (Crawled : 13:20) - biospace.com/
CBAY | $32.48 0.03% 8.4M
|
Health Technology
|
| O: 0.29%
H: 0.14%
C: -2.56%
meeting liver therapeutics
Q BioMed announces publication of pre-clinical research showing superior safety and efficacy against current first line therapy of its drug candidate Uttroside-B for liver cancer
Published: 2022-07-26 (Crawled : 13:20) - biospace.com/
QBIO | $0.0002 100.0% 1.1K
|
Professional, Scientific, and T...
|
| O: 0.25%
H: 200.0%
C: 200.0%
drug candidate research liver pre-clinical therapy cancer publication
Gainers vs Losers
| 74% | 26% |
Top 10 Gainers
MTTR | News M | $4.8 175.86% 63.6% 71M
|
AGBA | $2.5 100.0% 56.6% 200M
|
Finance
MLEC | $2.47 76.43% 42.62% 78M
|
n/a
NUWE | $0.334 29.96% 40.99% 2.5M
|
Manufacturing
EDBL | News | $6.26 66.49% 40.13% 16M
|
ATGL | $2.86 46.25% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6088 38.68% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.7M
|
Your saved searches
Save your searches and get alerts when important news are released.